ANN ARBOR, Mich., July 11 /PRNewswire-FirstCall/ -- Esperion Therapeutics,
Inc. (Nasdaq: ESPR) today announced that it has filed a registration statement
with the United States Securities and Exchange Commission (SEC). This
registration statement relates to a potential public offering of 4,000,000
shares of Esperion common stock. All shares will be offered by the Company.
In addition, the underwriters will have an option to purchase up to an
additional 600,000 shares from Esperion and selling stockholders to cover
over-allotments, if any. Lehman Brothers Inc. will act as bookrunner and
Citigroup Global Markets Inc., Needham & Company, Inc., and U.S. Bancorp Piper
Jaffray will act as co-managers.
A registration statement relating to these securities has been filed with
the SEC but has not yet become effective. These securities may not be sold
nor may offers to buy be accepted prior to the time the registration statement
becomes effective. This press release does not constitute an offer to sell or
the solicitation of an offer to buy nor shall there be any sale of these
securities in any state in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the securities laws of
any such state. When available, copies of the preliminary prospectus relating
to the offering may be obtained from Lehman Brothers Inc., Prospectus
Department, c/o ADP Financial Services, Integrated Distribution Services, 1155
Long Island Avenue, Edgewood, NY 11717, telephone: 631-254-7106, fax: 631-254-
7268.
Esperion Therapeutics
Esperion Therapeutics, Inc. discovers and develops pharmaceutical products
for the treatment of cardiovascular disease. Esperion intends to
commercialize a novel class of drugs that focuses on a new treatment approach
called "HDL Therapy," which is based on the Company's understanding of high-
density lipoprotein, or HDL, function. HDL is the primary facilitator of the
reverse lipid transport, or RLT, pathway by which excess cholesterol and other
lipids are removed from arteries and other tissues and are transported to the
liver for elimination from the body. Esperion's goal is to develop drugs that
exploit the beneficial functions of HDL within the RLT pathway. Esperion
currently has several product candidates under development for the treatment
of cardiovascular disease. Esperion is listed on the Nasdaq National Market
under the symbol "ESPR." For more information, visit http://www.esperion.com
Safe Harbor Statement
The information contained in this press release includes "forward-looking
statements" within the meaning of the Private Securities Litigation Reform Act
of 1995. These forward-looking statements are often identified by words such
as "hope," "may," "believe," "anticipate," "plan," "expect," "intend,"
"assume," and similar expressions. Forward-looking statements speak only as
of the date of this press release, reflect management's current expectations
and involve certain factors, such as risks and uncertainties, which may cause
actual results to be far different from those suggested by the Company's
forward-looking statements. These factors include, but are not limited to,
risks associated with: management's ability to successfully execute its
business strategies, including entering into any strategic partnerships or
other transactions; the progress and cost of development of the Company's
product candidates; the extent and timing of market acceptance of new products
developed by the Company or its competitors; dependence on third parties to
conduct clinical trials for these product candidates; the extent and timing of
regulatory approval, as desired or required, for the Company's product
candidates; the Company's dependence on licensing arrangements and strategic
relationships with third parties; clinical trials; manufacturing; the
Company's dependence on patents and proprietary rights; the procurement,
maintenance, enforcement and defense of the Company's patents and proprietary
rights; competitive conditions in the industry; business cycles affecting the
markets in which any of the Company's products may be sold; extraordinary
events and transactions; the timing and extent of the Company's financing
needs and the Company's access to funding, including through the equity
market; economic conditions generally or in various geographic areas; and
other factors. These factors are discussed in more detail in the Company's
filings with the Securities and Exchange Commission. The Company does not
intend to update any of these factors or to publicly announce the results of
any revisions to any of these forward-looking statements other than as
required under the federal securities laws.
Company Frank Thomas
Contact: VP, Finance and Investor Relations
Esperion Therapeutics, Inc.
(734) 222-1831
fthomas@esperion.com
SOURCE Esperion Therapeutics, Inc.
 back to top
Related links:
http://www.esperion.com
CONTACT:
Frank Thomas, VP, Finance and Investor
Relations of Esperion Therapeutics, Inc., +1-734-222-1831,
fthomas@esperion.com
|
